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Abstract
Background: Recurrence of colorectal cancer (CRC) may arise due to the persistence of drug-resistant and
cancer-initiating cells that survive exposure to chemotherapy. Proteins responsible for this recurrence include the
chemokine receptor CXCR4, which is known to enable CRC metastasis, as well as the cancer-initiating cell marker
and peptidase CD26, which terminates activity of its chemokine CXCL12.
Methods: We evaluated the expression and function of CXCR4 and CD26 in colon cancer cell lines and xenografts
following treatment with common chemotherapies using radioligand binding, flow cytometry, immunofluorescence,
and enzymatic assays.
Results: 5-Fluorouracil, oxaliplatin and SN-38 (the active metabolite of irinotecan), as well as cisplatin, methotrexate and
vinblastine, each caused decreases in cell-surface CXCR4 and concomitant increases in CD26 on HT-29, T84, HRT-18,
SW480 and SW620 CRC cell lines. Flow cytometry indicated that the decline in CXCR4 was associated with a significant
loss of CXCR4+/CD26- cells. Elevations in CD26 were paralleled by increases in both the intrinsic dipeptidyl peptidase
activity of CD26 as well as its capacity to bind extracellular adenosine deaminase. Orthotopic HT-29 xenografts treated
with standard CRC chemotherapeutics 5-fluorouracil, irinotecan, or oxaliplatin showed dramatic increases in CD26
compared to untreated tumors. Consistent with the loss of CXCR4 and gain in CD26, migratory responses to
exogenous CXCL12 were eliminated in cells pretreated with cytotoxic agents, although cells retained basal motility.
Analysis of cancer-initiating cell CD44 and CD133 subsets revealed drug-dependent responses of CD26/CD44/CD133
populations, suggesting that the benefits of combining standard chemotherapies 5-fluoruracil and oxaliplatin may be
derived from their complementary elimination of cell populations.
Conclusion: Our results indicate that conventional anticancer agents may act to inhibit chemokine-mediated
migration through eradication of CXCR4+ cells and attenuation of chemokine gradients through elevation of
CD26 activity.
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Background
Current standard of care for late stage and metastatic
colorectal cancer (CRC) includes surgical resection fol-
lowed by adjuvant 5-fluorouracil (5-FU) plus leucovorin,
and oxaliplatin (Ox) or irinotecan (IT) chemotherapy
until progression [1]. However, the development of drug
resistance and relapse with refractory disease limits the
5-year survival for metastatic CRC to less than 10 % [2].
Progression is driven in-part by the G-protein-coupled
chemokine receptor CXCR4, with high expression of
CXCR4 in CRC being associated with a greater risk of
recurrence and poor survival [3–5]. CXCR4 enables
migration towards its ligand CXCL12 (stromal cell-
derived factor-1; SDF-1) present in common sites of
metastasis such as the liver, lungs, lymph nodes and
bone [6–8]. In addition to assisting in the dissemination
of CRC, CXCR4 has also been shown to support growth
of metastases through its co-expression with glycopro-
tein CD133, a marker of cancer stem cells [9].
It is now recognized that most tumors arise from a
minority of cells capable of tumorigenesis [10]. These
‘cancer stem cells’ or ‘cancer initiating cells’ (CICs)
possess the capacity to both self-renew and differentiate
to re-populate the full phenotypic heterogeneity of the
tumor [11]. Surface antigens used to identify CICs
within CRC include CD133 [12] and the cell adhesion
molecule CD44 [11], however their roles in metastatic
disease remain controversial [13]. With the identification
of CICs, the possibility that selective action of drugs
may not eliminate the cell populations responsible for
recurrence has received attention. Recently, a subpopu-
lation of uniquely metastatic CICs has been reported to
co-express CD26 [14].
CD26 is a multifunctional cell-surface protein that is
variably expressed between different cancers but plays a
role in regulating cancer progression and spread [15]. Its
overexpression is linked to reduced invasiveness of
ovarian cancer [16] and it is down-regulated during
carcinogenesis of melanoma [17]. However, CD26 expres-
sion is up-regulated in renal cell carcinoma [18] as well as
papillary and follicular thyroid carcinomas [19, 20]. High
levels of CD26 expression is associated with worse survival
in CRC [21].
That the consequence of CD26 expression by tumors
remains equivocal is likely due to its diverse roles. In
addition to directly facilitating adhesion to the extracel-
lular matrix [22, 23], CD26 has two associated enzymatic
activities: an intrinsic dipeptidyl peptidase IV (DPPIV;
EC 3.4.14.5) activity and a hydrolase activity due to an-
chored ecto-adenosine deaminase (ADA; EC 3.5.4.4) for
which CD26 is the major binding protein [15]. Clearance
of adenosine by ADA can enhance immune surveillance,
a process that is inhibited by the accumulation of
adenosine in the tumor [24–26]. Through its peptidase
activity, CD26 controls CXCL12 concentrations [27] and
subsequent homing of hematopoietic progenitor cells to
the bone marrow [28] along with the metastatic behavior
of endometrial carcinoma [29] and Sézary cutaneous T
cell lymphoma [30]. The contrasting effects of CD26 in
different tumors may arise in part from the conse-
quences of different levels of DPPIV activity, leading to a
biphasic effect on the CXCL12 axis. Regional degrad-
ation of CXCL12 by DPPIV activity may serve to hone
the CXCL12 gradient in a similar fashion to its second
receptor CXCR7, preventing ligand-mediated receptor
desensitization of CXCR4 [31], but higher levels of
CD26 expression may result in gradient ablation.
Given the important roles of CXCR4 and CD26 in the
tumorigenesis and metastatic outgrowth of CRC, we
sought to observe whether their expression and function
might change following exposure to anticancer agents.
Our data show that the migratory phenotype of CRC
cells is suppressed immediately following exposure to
chemotherapeutic agents due to loss of CXCR4+ cells
and elevation of CD26 peptidase; and this is associated
with enrichment of a CD44+/CD133− cell subset.
Methods
Cell culture
HT-29, T84, HRT-18, SW480 and SW620 human CRC
cells and the additional cell lines mentioned were obtained
from the American Type Culture Collection. Cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM,
without antibiotics) supplemented with 5 % (HT-29, T84,
and HRT-18) or 10 % (SW480 and SW620) v/v heat-
inactivated newborn calf serum (NCS) and maintained as
stocks in 75-cm2 flasks at 37 °C in a humidified atmos-
phere of 90 % air/10 % CO2. Cells for use in binding assays
or for measurements of DPPIV enzyme activity were
seeded into 48-well plates at 50,000 cells/well and allowed
to adapt to culture for 48 h. The cells were then cultured
in medium containing 1 % NCS for a further 48 h. For flow
cytometry, cells were seeded into 6-well plates and allowed
to adapt for 48 h prior to treatment. Cells for migration as-
says were cultured and treated in 10-cm dishes. Anticancer
agents used were: 5-fluorouracil (5-FU), irinotecan (IT),
cisplatin (Cis), vinblastine (Vin), and methotrexate (MTX)
from Mayne Pharma Canada; oxaliplatin (Ox) from Sanofi
Canada; and SN-38 from Toronto Research Chemicals.
Where single drug concentrations are used, these were de-
fined as optimal (typically, just maximal) based upon the
response of the cells at that passage level and the lot(s) of
drug as obtained from the supplier(s).
Assay for cell-surface CD26 and CXCR4 on cell
monolayers
Cellular CD26 or CXCR4 protein levels were determined
on cell monolayers at 4 °C as previously described [32].
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Our assay for CD26 and CXCR4 measures native protein
expressed at the surface of viable cells, rather than total
cellular protein as with e,g, a western blot. Briefly, plates
were placed on ice, and the cultures were washed with
binding assay buffer (BAB; 137 mM NaCl, 5 mM KCl,
24.8 mM Tris, 0.7 mM Na2PO4, 0.5 mM MgSO4, 1 mM
CaCl2, pH 7.4), containing 0.2 %
w/v bovine serum albu-
min (BSA) followed by a 60-minute incubation with
125 μL BAB containing 1 % BSA and 1 μg/mL antibody
or isotype-matched control. Primary mouse anti-human
monoclonal antibody against CXCR4 (clone 12G5) and
mouse IgG2a isotype-matched control antibody (clone
G155-178) were from BD Pharmingen, mouse anti-human
monoclonal antibody against CD26 (clone M-A261) and
mouse IgG1 (clone W3/25) isotype controls were from
Cedarlane Laboratories, and secondary 125I-labeled goat
anti-mouse IgG, F(ab’)2 fragment was obtained from
PerkinElmer Life Sciences. After two washes with
BAB containing 0.2 % BSA, the cells were incubated for
60 minutes with 125 μL BAB containing 1 % BSA and
1 μCi/mL 125I-labeled goat anti-mouse IgG, F(ab’)2 frag-
ment. After three more washes the cells were solubilized
in 0.5 M NaOH and radioactivity was counted. To deter-
mine antigen-specific radioactivity, the nonspecific bind-
ing in the presence of the isotype control antibody was
subtracted from that obtained with the target antibody.
Cell counts were performed with a Coulter® model
ZM30383 particle counter (Beckman Coulter). Data are
expressed as antigen-specific radioactivity (cpm) per
100,000 viable cells.
Orthotopic tumor model
HT-29 cells (5 × 106 in 100 μL serum-free DMEM) were
injected s.c. into the flanks of six week old female CD-1
nu/nu mice (Charles River) and tumors were allowed to
grow for 18–20 d until approximately 7 mm in diameter.
The tumor tissue donors were euthanized under
ketamine/xylazine anesthesia, tumors were harvested
aseptically, and all non-tumor tissue was dissected away.
The tissues were washed in ice-cold DMEM and cut
into ~1 mm3 pieces for tumor transplantation. Recipient
immunodeficient mice were anesthetized with 70 mg/kg
ketamine and 14 mg/kg xylazine i.p. and treated pro-
actively with 0.3 mg/kg buprenorphrine i.p. for post-
surgical analgesia. A 1-cm abdominal incision was made
to the right of midline and the distal small intestine was
exteriorized to locate the ileocecal junction. The proximal
end of the ascending colon was identified and abraded
gently with the wooden end of a cotton-tipped applicator.
Three 1-mm3 tissue pieces were sutured onto the muscu-
laris of the proximal ascending colon, taking care not to
pierce the colon wall. The intestine was interiorized and
the incision was sutured. Twenty-six and 28 days follow-
ing surgery, mice were weighed and injected i.p. with
drugs or vehicle control (saline). Two days after the
second dose, they were euthanized. The treatment and
analysis period of days 26–30 represented the best time
window between formation of an anatomically well-
integrated tumour (by day 24) and a risk of occlusion
of the intestinal lumen by the expanding tumour (from
day 32) in the case of HT-29 cells. Tumors were
harvested and tissues were weighed and snap-frozen in
liquid nitrogen or fixed in 4 % formaldehyde for later
analysis. All procedures were approved by the Carleton
Animal Care Facility University Committee on Laboratory
Animals at Dalhousie University.
Immunolocalization of CD26 and CXCR4 in tumours
For visualisation of CD26, tumors were frozen in OCT®
and sectioned at a thickness of 8 μm with a Leica CM
3050S cryostat (Leica Microsystems). Sections were
mounted on slides and maintained at −20 °C. For immu-
nohistochemistry, all steps were carried out at 4 °C, un-
less otherwise described. Sections were thawed briefly,
rinsed with phosphate-buffered saline (PBS) containing
1 mg/mL BSA and 0.1 % Tween 20 (PBS/BSA/Tween),
blocked with 3 % goat serum in PBS/BSA/Tween for
30 min, then incubated with 25 μL of PBS/BSA/Tween
containing 5 μg/mL mouse anti-human CD26 primary
antibody for 2 h in a humidified chamber. Sections were
washed three times with PBS/BSA/Tween, and then
incubated with 25 μL of PBS/BSA/Tween containing
2 μg/mL of an Alexa Fluor® 488-conjugated goat anti-
mouse IgG secondary antibody for 2 h in a humidified
chamber in the dark. Slides were washed a further three
times, post-fixed with PBS containing 10 % formalde-
hyde for 10 min at room temperature, and rinsed with
distilled water. Coverslips were mounted on sections
using low-fade Gel/mount® and fluorescence was ob-
served using a Leica DM 2000 fluorescence microscope
(Leica Microsystems).
To observe CXCR4, formalin-fixed and paraffin wax-
embedded tissue was sectioned and processed for
immunoperoxidase procedures. Deparaffinised sections
were subjected to antigen retrieval using 10 mM citrate
buffer, pH 6.0 at 95 °C in a microwave. Rinsed sections
were then stained for CXCR4 using the same procedure
as for CD26, except that the bound primary antibody
was identified using a Vectastain ABC kit (Vector
laboratories, Burlingame, CA). Quantitation was per-
formed in the absence of counterstain; the distribution
of CXCR4 was visualised with a Harris’ hematoxylin
counterstain.
Levels of CD26 or CXCR4 were analyzed with
QCapture Pro® software. The average staining in-
tensity of the tumor was measured in a randomly-
selected area of constant dimension, determined by a
blinded observer.
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Flow cytometry
HT-29 cells were released from 6-well plates by TrypLE™
Express. Cells were washed with chilled flow buffer (PBS,
25 mM HEPES, 1 mM EDTA, 1 % BSA) and resuspended
in 2 μg/mL CXCR4-APC (clone 12G5; BD Pharmingen)
and CD26-FITC (clone M-A261; Serotec), combined
CD26-FITC (clone M-A261; Serotec), CD44-APC (clone
G44-26; BD Pharmingen), CD133-PE (clone AC133;
Miltenyi Biotec), or fluorophore-tagged isotype controls
(Miltenyi Biotec) for 45 min at 4 °C. Cells were then
washed twice with flow buffer and resuspended in BSA-
free flow buffer for analysis. Flow cytometry analysis was
carried out with a BD FACSCalibur™ flow cytometer (BD
Biosciences). Cell debris and aggregates were excluded
based on scatter signals and 10,000 events were captured
per sample. Data were analyzed using Flowing Software
version 2.5.0 (University of Turku, Turku, Finland).
Following labeling with CD26-PE (clone M-A261;
Serotec) cells were stained with annexin-V-FITC and
propidium iodide (PI) according to manufacturer’s pro-
tocol (Roche Diagnostics) for detection of necrotic,
apoptotic, and live cells. Analysis was carried using a
Guava® easyCyte™ 8HT flow cytometer and associated
InCyte software (Millipore).
DPPIV activity and ADA-binding capacity assays
DPPIV enzyme activity was measured spectrophoto-
metrically using Gly-L-Pro p-nitroanilide (Gly-Pro-pNA;
Sigma-Aldrich) as the DPPIV substrate [32]. To measure
the cellular capacity for ecto-ADA binding, HT-29 cells in
48-well plates were treated with 10 μg/mL calf spleen
ADA1 (Worthington Biochemical) in medium for 60 min
at 37 °C and then assayed for bound ADA using 1 μg/mL
rabbit anti-bovine ADA antibody (Alpha Diagnostic
International) and 0.5 μCi/mL 125I-labeled donkey anti-
rabbit secondary antibody F(abʹ)2 fragment (Amersham
Biosciences), using the procedures previously de-
scribed [32].
Migration assays
Transwell® 8 μm pore size polycarbonate membrane in-
serts (Corning) were coated overnight at 37 °C with
1 μg/mL type V collagen. Drug- and vehicle-treated cells
were released from culture by brief exposure to trypsin
and resuspended at 0.5 - 2.5 × 106 cells/mL in serum-
free DMEM containing 1 mg/ml BSA. One hundred
microlitres of cell suspension were added to the upper
chamber, and 600 μL of DMEM containing 1 mg/mL
BSA and 100 ng/mL CXCL12 or vehicle control were
added to the bottom chamber. Chambers were incubated
for 18 h at 37 °C, and filters were fixed and stained with
Mayer’s hematoxylin. Cells remaining on the upper sur-
face of the membrane were removed using a cotton-
tipped applicator, and the filter was mounted using
Cytoseal 60®. Cells that had migrated to the lower
surface of the membrane were counted microscopically
by a blinded independent observer.
Statistical methods
Statistical significance of differences between data was
determined using ANOVA or t-test models as indicated.
Linear regression analysis was performed to identify pa-
rameters affecting the percent change in cells within a
population after being subjected to a specific drug.
Regression analysis and Tukey’s post hoc tests were
completed using R version 3.0.2 (Vienna, Austria).
Results
Exposure to chemotherapeutic drugs leads to opposing
changes in cell-surface expression of CXCR4 and CD26 in
surviving populations of colon cancer cells
We first screened a range of human CRC cell lines
(HT-29; adenocarcinoma, T84; CRC lung metastasis,
HRT-18; ileocecal adenocarcinoma, SW480; primary ade-
nocarcinoma, and SW620; secondary adenocarcinoma
lymph node metastasis) for their endogenous expression
of CXCR4 and CD26 using a radioimmunobinding assay,
and evaluated possible changes in each marker in
response to exposure to chemotherapeutic agents. Basal
expression of CXCR4 varied between CRC cell lines with
HT-29 cells having the highest expression (Table 1). Basal
cellular expression of CD26 also varied greatly, with ap-
proximately 50-fold difference between cell lines and was
broadly related to the degree of cellular differentiation,
being highest in cells with a clear epithelial morphology
(T84, HT-29), intermediate in cells that grow with a more
extended morphology (HRT-18) and lowest in cells with
rounded morphology and low substratum adherence
(SW480, SW620) (Table 2). CD26 was present at approxi-
mately half the level at the surface of a metastasis-derived
cell line SW620 compared with the paired cell line from
the primary tumour SW480 [33] (Table 2).
These different cell lines were initially treated with
chemotherapeutic agents that have entirely distinct
mechanisms of action, so as to identify changes that
would not be selective to any particular cellular target:
5-FU (pyrimidine antagonist), Cis (DNA cross-linker),
Vin (microtubule poison), or MTX (folate antagonist).
Following initial time course experiments (binding
assays completed 0 – 72 h post-treatment; data not
shown) cell-surface expression of CXCR4 and CD26 was
determined at 48 h for subsequent experiments (Tables 1
and 2). Without exception and with the same effect or
trend across five distinct CRC cell lines, each of these
diverse agents led to a decrease in cell surface CXCR4
(Table 1) and conversely caused an increase in the net
cell surface CD26 (Table 2).
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In each case the maximal degree of change differed
considerably depending upon the cell line and the
responsiveness to perturbation was not the same for
CXCR4 and CD26 (Tables 1, 2). For example, in the
paired cell lines SW480 and SW620, which are derived
from the same patient at different stages of CRC [33],
SW480 cells (from the primary tumour) showed a more
robust elevation of CD26 while SW620 cells (from a
later metastasis) showed the more dramatic change in
CXCR4. These and other observations (see below) sug-
gested that regulation of changes in these two proteins
were affected through different mechanisms.
Decline in surface expression of CXCR4 and increase in
CD26 is due to a drug-induced decrease in CXCR4+ cells
and enrichment of CD26 expression in distinct
populations
Due to significant basal levels of both CXCR4 and CD26
while demonstrating the most consistent changes to a
range of different chemotherapeutics, we focused on the
responses of HT-29 cells as our model system.
We treated the cell population with chemotherapeu-
tics including those used above but adding oxaliplatin
(Ox; DNA cross-linker) and irinotecan (IT; topoisom-
erase 1 inhibitor), both drugs routinely used for treat-
ment of human CRC [34]. We also evaluated the
effect of the active metabolite of IT, SN-38. Treat-
ment with the active agents progressively decreased
the proportion of CXCR4+ cells in the cell population.
The loss of CXCR4+ cells due to drug exposure
showed substantial dose-dependent loss of CXCR4+
cells following treatment with agents 5-FU, Ox, Vin,
Cis, MTX and SN-38 at the concentrations tested
(Fig. 1a, Additional file 1: Figure S1a).
Treatment with 5-FU, Vin, Cis, and MTX consistently
elevated CD26 (Fig. 1b, Additional file 1: Figure S1b), re-
flective of a general up-regulation of CD26. Both SN-38
and IT were capable of elevating CD26 when used at
higher concentrations than Fig. 1a, although SN-38 was
more potent as expected (Fig. 1b).
Co-staining of both CXCR4 and CD26 revealed roughly
equal representation of CXCR4+/CD26−, CXCR4−/CD26+,
and CXCR4+/CD26+ populations, with a majority (~70 %)
of cells staining CXCR4−/CD26−. At the moderate con-
centrations used, all drug treatments substantially reduced
the proportion of CXCR4+/CD26− cells, with little change
Table 1 Constitutive expression and decrease of CXCR4 at the surface of human colorectal carcinoma cells due to anticancer drugs
Cell line Basal CXCR4 expression
(cpm/105 cells)
Drug treatment
5-FU Cis Vin MTX
Maximal decrease (% from control)
HT-29 470 ± 52 75 ± 6.1* 72 ± 6.3* 75 ± 12* 56 ± 7.6*
T84 220 ± 53 42 ± 15 48 ± 22 27 ± 4.4 39 ± 21
HRT-18 62 ± 27 59 ± 18 29 ± 11 76 ± 8.4 63 ± 27
SW480 230 ± 41 24 ± 13 32 ± 13 71 ± 7.6* 24 ± 6.4
SW620 80 ± 29 70 ± 7.0 77 ± 13* 72 ± 18 73 ± 3.0
The relative basal cell-surface protein expression for each cell line was summarized from 8–28 independent experiments. Cells were treated with drugs (5-FU, 5-
fluorouracil [0.1 – 1,000 μg/mL]; Cis, cisplatin [0.001 – 10 μg/mL]; Vin, vinblastine [0.001 – 10 μg/mL]; MTX, methotrexate [0.1 – 1,000 μg/mL]) and cell
surface expression of CXCR4 was determined by radioimmunobinding assay 48 h later. Maximal decrease of CXCR4 was recorded from 3–8 independent
dose–response experiments for each drug and cell line. Data are shown as mean % decreases ± SE. *, significant % decrease due to drug, P < 0.05 using paired t-test
Table 2 Constitutive expression and increase of CD26 at the surface of human colorectal carcinoma cells by anticancer drugs
Cell line Basal CD26 expression
(cpm/105 cells)
Drug treatment
5-FU Cis Vin MTX
Maximal increase (% over control)
HT-29 1,300 ± 140 30 ± 5.8** 72 ± 26*** 41 ± 10** 26 ± 6.4**
T84 780 ± 69 84 ± 14* 61 ± 42 78 ± 6.6 73 ± 42
HRT-18 370 ± 64 17 ± 9.1* 19 ± 9.1 23 ± 12 18 ± 9.4**
SW480 55 ± 15 96 ± 58* 90 ± 66 100 ± 59** 170 ± 150
SW620 26 ± 12 36 ± 31 28 ± 30 45 ± 43 53 ± 49
The relative basal cell-surface protein expression for each cell line was summarized from 12–5 independent experiments. Cells were treated with drugs (5-FU,
5-fluorouracil [0.1 – 1,000 μg/mL]; Cis, cisplatin [0.001 – 10 μg/mL]; Vin, vinblastine [0.001 – 10 μg/mL]; MTX, methotrexate [0.1 – 1,000 μg/mL]) and cell surface
expression of CD26 was determined by radioimmunobinding assay 48 h later. Maximal up-regulation of CD26 was recorded from 3–7 independent dose–response
experiments for each drug and cell line. Data are shown as mean % increases ± SE for the moderate/high CD26-expressing cell lines, and mean numerical
increases (cpm/105 cells) ± SE for the low expressers. *, significant increase due to drug, P < 0.05; **, P < 0.01; ***, P < 0.001, using paired t-test
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Fig. 1 (See legend on next page.)
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in proportions of CXCR4−/CD26− and CXCR4+/CD26+
populations (Fig. 1c). As expected, SN-38, Vin, MTX, and
to a lesser extent 5-FU enriched for CXCR4−/CD26+ cells
(Fig. 1c).
Increase in CD26 and decline in tumour cell expression of
CXCR4 occurs in vivo and is not an artefact of cytotoxicity
We sought to confirm our results using an orthotopic
mouse model of nu/nu mice with HT-29 colorectal
tumors growing within the large intestine. Established
tumors were treated systemically with saline or 5-FU,
Ox or IT prior to being stained by immunofluorescence
(CD26) or immunoperoxidase (CXCR4) (Fig. 1d). Tu-
mors of treated mice showed a marked increase in CD26
protein based on fluorescent intensity compared to
controls (P < 0.05), consistent with in vitro data from cell
monolayers. Interestingly Ox, which showed little po-
tency to elevate CD26 in vitro, was the most effective in
enhancing CD26 in vivo (Fig. 1d; mean increase 57 %
compared with 28 % for 5-FU and 48 % for IT), showing
that additional influences may modify the phenomenon
in the whole animal.
A decline in CXCR4 within the tumour parenchyma
due to drugs was also observed after staining with immu-
noperoxidase (Fig. 1d), although quantitative analysis
showed statistical significance only with the 50 mg/kg
dose of 5-FU (45.7 ± 1.5 compared with 55.9 ± 3.5 for the
saline control, P = 0.01). Quantification of tumour cell
CXCR4 was complicated by tumour heterogeneity and the
expression of CXCR4 on other cells within the tumour
tissue (compare controls in Fig. 1d).
Given the acute treatment regimen and follow-up
period, no effect on tumor growth was generally ob-
served at time of sacrifice compared to saline-treated
mice, with the exception of the mice treated with the
highest dose (50 mg/kg) of 5-FU, which exhibited a sta-
tistically significant weight loss (4 %; 1.0 ± 0.4 g).
Although flow cytometry events were gated to elimin-
ate nonviable cells, we sought to exclude the possibility
that changes in these surface proteins at high drug doses
might be a consequence of toxicity. Staining with
annexin V-PI was used to distinguish between viable cells
and cells in the early stages of apoptosis or necrosis. Data
for CD26, which responded at higher drug doses, are
shown in Additional file 2: Figure S2 and reveal that only
live (annexin V−/PI−) cells contributed to increased CD26
levels following drug treatment. To determine whether
changes in overall expression were confined to the cell
surface or due to changes in gene expression, the fold-
change of CXCR4 and CD26 mRNA following 12 hour
treatment was quantified by qPCR (Additional file 3:
Figure S3, Additional file 5: Supplementary Methods).
Chemotherapeutic drugs consistently decrease CXCR4
and elevate CD26 protein expression on human CRC cells
but the two responses have different kinetics and
maxima
Time courses of changes in cell-surface proteins in re-
sponse to drug treatments differ between CXCR4 and
CD26, but in general begin 24–72 h after drug addition
(data not shown). A more comprehensive assessment of
the decrease in CXCR4+ cells with a range of chemo-
therapeutic agents (Additional file 5: Table S1) showed
that the maximum decrease averaged 78.6 % and was
not significantly different between six drug treatments
(P = 0.26), consistent with the view that different agents
act by eliminating the fixed proportion of CXCR4+ cells.
The maximum increase in CD26 expression, however,
varied greatly as a consequence of different drug treat-
ments (Additional file 5: Table S1), ranging from 22 %
for Ox to 72 % for Cis. This again is consistent with the
expectation that there is an elevation of CD26 on all sur-
viving cells, which will be dependent upon signalling
pathways that are initiated differentially by different
drugs. The two extremes of maximal effect for an in-
crease in CD26 exist for two agents (oxaliplatin and cis-
platin) that have the same mechanism of cytotoxicity;
suggesting that the mode of up-regulation of CD26 is
separable from pathways that lead to cell death.
Increased CD26 cell-surface expression is accompanied by
elevated DPPIV activity and ecto-ADA binding following
chemotherapeutic drug treatment
CD26 is the major cellular anchoring protein for ecto-
ADA and has an intrinsic dipeptidyl peptidase activity
[15], therefore we examined the functional consequence
of increased CD26 on HT-29 cells directly in parallel
with measurements of the surface abundance of CD26
(See figure on previous page.)
Fig. 1 Anticancer agents decrease CXCR4 while increasing CD26 expression in the HT-29 cell line. HT-29 cells were treated with chemotherapeutic
drugs (μg/mL) and stained for flow cytometry analysis of CXCR4 (a; mean % change in CXCR4 expression from vehicle control ± SE, n = 3;
*, P < 0.01 by two-way ANOVA) or CD26 (b; mean % change in CD26 expression from vehicle control ± SE, n = 6; *, P < 0.05 by two-way ANOVA).
c Dual-stain of CXCR4 and CD26 following drug treatment (5-FU = 1, Ox = 1, IT = 1, SN-38 = 0.1, Vin = 0.1, Cis = 1, MTX = 1 μg/mL; mean % of each
population following vehicle control, n = 5; *, P < 0.01 by two-way ANOVA). d Mice (nu/nu) with HT-29 colorectal tumors growing within the large
intestine were treated with saline, 10 or 50 mg/kg 5-FU, 0.5 mg/kg Ox, or 10 mg/kg IT four and two days before the tumors were harvested.
Tumor sections were immunostained using anti-CD26 antibody or isotype control antibody (inserts); or are shown with peroxidase-stained CXCR4
with a hematoxylin counterstain. Representative images of four mice per group
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(Fig. 2). Treatment with 5-FU (Fig. 2a), Cis (Fig. 2b), Vin
(Fig. 2c), or MTX (Fig. 2d) revealed closely comparable
proportional (%) increases in ecto-ADA binding capacity
and DPPIV activity compared with those for CD26 pro-
tein, showing that the additional CD26 at the cell surface
is functional.
We have shown that ecto-ADA plays a role in the
auto-regulation of CD26/DPPIV in that it permits in-
creased down-regulation of CD26/DPPIV due to adeno-
sine in the hypoxic tumour environment [32]. Moreover,
decreases in DPPIV activity permit increased levels of
CXCL12, which is the major substrate of DPPIV [35].
Increased CXCL12 may then down-regulate CXCR4
[36]. We therefore questioned whether changes in these
enzyme activities could be responsible for the con-
comitant regulation of CXCR4 with CD26. However, an
increase in ecto-ADA would reduce ambient adenosine,
which our earlier findings indicate would not reduce
CXCR4 expression [37]. Inhibition of DPPIV with dipro-
tin A did not alter 5-FU- induced down-regulation of
CXCR4 (Fig. 2e). Similarly, diprotin A inhibition of
DPPIV did not alter 5-FU-induced CD26 up-regulation
(Fig. 2f ). We conclude that secondary alterations in
ecto-ADA and DPPIV activities do not contribute to the
linked and opposing changes in CXCR4 and CD26 after
chemotherapeutic drug exposure.
Exposure of CRC cells to chemotherapeutic drugs
eliminates subsequent CXCL12-driven cell migration
Metastasis and growth of many cancers is driven by
CXCL12 through CXCR4 and may be modulated by
DPPIV-mediated CXCL12 degradation [29, 38]. HT-29 cells
that had been exposed to drugs were tested for their migra-
tion toward CXCL12 in a chemotaxis assay (Fig. 3a-d). The
surviving cells remained motile following treatment with
5-FU (Fig. 3a), Cis (Fig. 3b), Vin (Fig. 3c), or MTX (Fig. 3d),
showing the same background ability to cross the
collagen-coated polycarbonate filters as untreated cells
over an 18 h period. However, pre-treatment with any of
these agents completely abrogated CXCL12-mediated
migration, showing that the reduction in CXCR4 when
accompanied by enhancement of functional CD26 leads
to a complete suppression of migration toward CXCL12,
and extends observations of reduced migration of SW480
towards CXCL12 in the presence of irinotecan [39]. Treat-
ment with CXCL12 for 48 hours resulted in decreased
cell-surface CXCR4 as expected (Fig. 3e), without altering
CD26 levels (Fig. 3f).
Anticancer agents enrich for CD26+ and CD44+
populations while decreasing CD133- populations
Pang and colleagues [14] have provided evidence that
CD26 is a marker of metastatic CRC stem cells. How-
ever, the latter finding conflicts with the long-established
belief that CD26, as the major intestinal ADA-binding
protein and DPPIV [15], is a marker of differentiated
epithelial cells in the intestine [40, 41]. For this reason
we examined the co-expression of established CRC
‘stem cell’ (CIC) markers CD44 and CD133 alongside
CD26.
Triple staining of HT-29 cells for CD26, CD44 and
CD133 revealed consistent changes in response to
treatment with chemotherapeutic drugs. Regression re-
sults from a model fitting to the percent change in num-
ber of cells as a function of principal cell populations
(frequency >1 %) and drugs (Marker and Drug variables)
are shown in Additional file 5: Table S2 and the results
of post hoc tests for percent change between cell popula-
tions are shown in Additional file 5: Table S3. Residual
checks showed no departure from the assumptions of
normality, independence and constant variance. Indi-
vidual significance tests of the regression coefficients
show that ‘DrugOx’ (oxaliplatin) had a significant effect
on the average percent change in the number of cells
with respect to a control group, while controlling for the
marker populations. Populations CD26−/CD44−/CD133+
and CD26+/CD44−/CD133− also had a statistically sig-
nificant contribution to the response (Additional file 5:
Table S2). Tukey’s post hoc tests for percent change be-
tween cell populations revealed CD26+/CD44−/CD133−
cells differed significantly from CD26−/CD44−/CD133+
and CD26+/CD44+/CD133+ populations in their response
to anticancer agents (Fig. 4, Additional file 5: Table S3).
The changes across drug treatments within the five major
populations and the statistical differences are summarised
in Fig. 4. Populations CD26-/CD44+/CD133+, CD26-/
CD44+/CD133-, and CD26 + CD44 + CD133- each repre-
sented less than one percent of all cells.
Within subpopulations, cells treated with drugs having
substantially diverse mechanisms of action showed general
decline in CD133 (Additional file 4: Figure S4a) and in-
creases in CD44 (Additional file 4: Figure S4b) and CD26
(Additional file 4: Figure S4c). Increases in CD26 expres-
sion were seen across all combinations of cellular expres-
sion of CD133 and CD44. However overall CD26 elevation
was most marked in association with the CD44+/CD133−
phenotype and least associated overall with the opposite
CD44−/CD133+ phenotype (Additional file 4: Figure S4c).
Interestingly, Ox-treated cells were distinctive in that
CD26 expression actually declined in association with
CD44−/CD133+ cells in contrast to all other drug treat-
ments (Additional file 4: Figure S4c).
Discussion
Drivers in the recurrence of CRC include the chemokine
receptor CXCR4, its ligand CXCL12, and the ectoenzyme
CD26 for which CXCL12 is a substrate [35]. We find that
this regulatory framework is altered in the population of





Fig. 2 (See legend on next page.)
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surviving cells following incomplete eradication by che-
motherapeutic agents.
A diverse range of established cytotoxic agents share
the ability to down-regulate CXCR4 but up-regulate
CD26, in this case on five different CRC cell lines (T84,
HT-29, HRT-18, SW480, SW620). Furthermore, sup-
pression of the CXCL12-CXCR4 axis due to loss of
CXCR4 is potentially accentuated by this concomitant
up-regulation of CD26, because its DPPIV activity
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Fig. 3 Prior treatment with anticancer agents significantly diminishes chemotaxis toward CXCL12. Cells were pre-treated either with vehicle
control or 2 μg/mL a 5-FU; b Cis; c Vin; or d MTX for 48 h, isolated from culture and then assayed for chemotaxis toward 100 ng/mL CXCL12
(hatched bars) or vehicle control (light bars). Mean ± SE (n = 6). *, P < 0.01 by ANOVA. e CXCL12-dependent loss of CXCR4 cell-surface expression.
f cell-surface CD26 is unaffected by CXCL12
(See figure on previous page.)
Fig. 2 Adenosine deaminase-binding capacity and dipeptidyl peptidase IV activity increase in parallel with CD26 protein. Cells were treated with
vehicle (light bars) or 2 μg/mL a 5-FU; b Cis; c Vin; or d MTX (hatched bars) and assayed when the maximal effect was attained, at 24 h (Vin) or
48 h (5-FU, Cis, MTX) for CD26 protein, ADA-binding capacity, and DPPIV activity. Mean ± SE (n = 4). *, P < 0.01 by Student’s t-test. e Decrease in
CXCR4 due to 20 μg/mL 5-FU is maintained in the presence of the DPPIV enzyme inhibitor diprotin A (75 μM). f Increase in CD26 due to 20 μg/mL
5-FU is maintained in the presence of the DPPIV enzyme inhibitor diprotin A. Mean ± SE (n = 4). *, P < 0.01 by ANOVA
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reduction in the bioactivity of the chemokine ligand as
well as the decline in its receptor. These effects on
CXCR4 and CD26 were independent of the cytotoxic
mechanisms of action of these drugs, which acted
through DNA cross-linking (Cis, Ox), inhibition of DNA
synthesis (5-FU, MTX), microtubule disruption (Vin) or
topoisomerase inhibition (IT; SN-38). The ability of
agents (e.g. MTX, VB) that are not components of
current cytotoxic regimens may allow them to be added
in late-stage disease to manipulate CXCR4/CD26 levels
without contributing to existing dose-limiting toxicities.
Loss of the average CXCR4 expression of the cell
population was due to selective elimination of CXCR4+
cells. The same diverse collection of agents caused an
increase in the abundance of CD26 at the CRC cell
surface after treatment. In this case the change in CD26
did not result from selection toward a greater proportion
of CD26+ cells, but an overall increase in CD26 net cell-
surface expression. This was found to be (i) an authentic
increase on viable cells, (ii) an increase in fully-functional
CD26 (able to bind ecto-ADA and with DPPIV activity),
(iii) independent of ambient levels of CXCL12, and (iv)
regulated separately from DPPIV activity (as was the de-
crease in CXCR4). (This phenomenon of chemotherapy-
induced CD26 elevation was also reproducible in four
other, non-CRC carcinoma cell lines (LNCaP and PC-3;
prostate, A549; lung, and T-47D; breast) and a non-
epithelial cancer cell line (SH-SY5Y; neuroblastoma); data
not shown).
The mechanism of chemotherapeutic drug-induced
elevation of CD26 clearly differs from the simple select-
ive process of CXCR4 and remains under investigation.
For most drugs the EC50 for CD26 elevation did not
differ significantly from that for reduction of CXCR4,
although for cisplatin the concentration required to
elevate CD26 was 10-fold higher than that required to
reduce CXCR4+ cells, indicating that the mechanisms
are not linked in a consistent manner. Furthermore, the
maximum decrease in CXCR4 was essentially the same
for all drugs at around ~ 80 % (Additional file 5: Table S1),
consistent with a cell selection process in which the out-
come is defined by the survival of CXCR4+ cells. However,
the maximum achievable elevation for CD26 varied be-
tween 22 % and 72 %, revealing differences in how this
outcome is signalled. These two extremes in fact corre-








































































Fig. 4 Percent change of cell populations following treatment
with anticancer agents. Heatmaps of fold-change in the five
CD26/CD44/CD133 populations present within HT-29 cultures at a
frequency >1 % (n = 6). Oxaliplatin (Ox) was identified as a covariate
having a significantly different effect on cell populations. Brackets
highlight significant differences between percent changes in populations
following drug treatment
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most similar in their cytotoxic mode of action of all the
major drugs studied, suggesting a distinction from path-
ways that lead to cell death. It was also noted that IT was
more able to elevate CD26 than would be expected if
compared with its active metabolite SN-38. The data
overall point to a substantially different pathway by
which these agents up-regulate CD26, albeit one that is
initiated by many cytotoxic agents. It is worth noting
that general approaches to kill CRC cells by nonspecific
means (exposure to pH 8.6, 300 mM NaCl or 0.01 % w/
v deoxycholate) neither elevated CD26 nor selected for
an altered CXCR4+ subpopulation (data not shown).
HT-29 cells that had survived treatment with chemo-
therapeutic agents at modestly cytotoxic concentrations
were fully proficient in terms of their capacity for move-
ment at 48 h after treatment - basal migration did not
differ from that of untreated cells. However, the directed
migration toward CXCL12 was completely ablated. We
attribute this loss of migration towards CXCL12 to the
decline in CXCR4 and concomitant increase in DPPIV
activity through gain of CD26. Comparable treatment
with these drugs had no effect on the (low) levels of the
alternate CXCL12 receptor CXCR7 expressed at the sur-
face of human CRC cell lines (data not shown).
Outgrowth of residual disease has been attributed to a
subpopulation of drug-resistant CICs capable of dif-
ferentiating into the different cellular hierarchies that
make up the overall tumor bulk [11, 42]. Chronic treat-
ment of CRC cell lines with 5-FU or Ox enriches for
CIC markers CD44 and CD133 [43], and irinotecan-
treated xenografts show a greater frequency of CD44+
cells [44]. This implicates both CD44 and CD133 as
markers for the putative CRC CIC subset. Although clas-
sically recognized as a marker of differentiation [40, 45],
CD26 expression has recently been reported to define a
metastatic subpopulation of CICs within CRC and
associated with development of metastasis in CRC
patients [14, 21]. The paradox of CD26 being both a dif-
ferentiation marker and correlate of cancer aggression
likely reflects its multiple roles [15] and the consequence
that its impact on cell function is context dependent.
Using primary colon cancer cells 5-FU has been re-
ported to increase the CD26+/CD133+ subpopulation
[14]. This is consistent with our finding that CD26 is
increased across all cell subpopulations after 5-FU
treatment. We do however extend the observation to
show that many agents increase CD26 levels on CRC
cells, and report for the first time that treatment with
the agents currently used to treat CRC favors the emer-
gence of a CD26+/CD44+ cell population. This is an in-
triguing finding in that there is increased co-expression
of two markers both interact with the extracellular
matrix and might be able to cooperate in the process of
metastasis associated with CD26 identified by Pang and
colleagues [14]. CD26 is known to associate with both fi-
bronectin and collagen [46, 47] while CD44 is a receptor
for hyaluronic acid (HA) and functions in cell adhesion
and tumorigenicity [48, 49].
Conclusion
Collectively, our data show that an important signaling
mechanism of cancer metastasis may be down-regulated
in parallel to the cytotoxic effects of chemotherapy. As
well as adding to our knowledge of how existing agents
work, this may have implications for understanding the
cellular phenotype in residual disease after chemo-
therapy, particularly where a less dose intense approach is
used. Understanding the post-treatment cellular pheno-
type, and why some patients relapse despite therapy is
crucial. Phenotyping of circulating tumor cells post-
chemotherapy offers a sensitive method of detecting sur-
viving cancer cells following adjuvant therapy [50]. Our
findings suggest that it will be productive to evaluate the
CD26/CD44/CD133/CXCR4 status of refractory cancer
cells in future studies of CRC.
Additional files
Additional file 1: Figure S1. Anticancer agents decrease CXCR4+ cells
and increase cell-surface expression of CD26 in the HT-29 cell line.
(A) Representative histograms showing the loss of CXCR4+ cells following
treatment with 5-FU or SN-38 as indicated, with concentrations in μg/mL.
(B) Representative histograms showing the overall enhancement (rightward
shift) following treatment with 5-FU or SN-38 as indicated (concentrations in
μg/mL). Grey lines show frequency distributions of vehicle control-treated
cells. (EPS 972 kb)
Additional file 2: Figure S2. Chemotherapeutic drugs increase CD26
protein expression on live cells but do not alter immunoreactivity against
dead cells. HT-29 cells were co-stained with CD26-PE-annexin V-PI and
gated to necrotic (A; annexin V+/PI+), apoptotic (B; annexin V+/PI−), or
live (c; annexin V−/PI−) populations following treatment. Mean channel
fluorescence of CD26-PE ± SE (n = 6). *, P < 0.01 compared to vehicle
control by two-way ANOVA. (EPS 833 kb)
Additional file 3: Figure S3. Fold-change in CXCR4 and CD26 mRNA
expression following treatment with anticancer agents. Cells were
pre-treated either with vehicle control or 2 μg/mL 5-FU, Cis, Vin, or MTX
for 12 h, isolated from culture and then assayed for CXCR4 (grey bars)
or CD26 (white bars) mRNA qPCR by SYBR green. Mean ± SE (n = 3).
(EPS 511 kb)
Additional file 4: Figure S4. Treatment with diverse anticancer agents
increases CD26 while also enhancing CD44+, but lowering CD133+
populations. Heatmaps of fold-change in cellular expression of (A) CD133,
(B) CD44, and (C) CD26 within different CRC subpopulations separated by
pairs of the alternative markers (n = 6). (EPS 812 kb)
Additional file 5: Supplementary Methods: Real-time (q)PCR.
Table S1: Comparison of the effects of chemotherapeutic agents on
cell-surface CXCR4 and CD26 on remaining viable HT-29 cells following
48 h of exposure. Table S2: Estimation results for regression model with
cell Marker and Drug as covariates. Table S3: Confidence level tests for
percent change between cell populations. (DOC 53 kb)
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